About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. Its primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells. The Company's product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: AQXP
- Previous Close: $18.36
- 50 Day Moving Average: $18.18
- 200 Day Moving Average: $13.91
- 52-Week Range: $6.01 - $19.97
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.15
- P/E Growth: 0.00
- Market Cap: $428.41M
- Outstanding Shares: 23,423,000
- Beta: -17.36
- Return on Equity: -27.43%
- Return on Assets: -25.84%
Companies Related to Aquinox Pharmaceuticals:
- Current Ratio: 17.13%
- Quick Ratio: 17.13%
What is Aquinox Pharmaceuticals' stock symbol?
Aquinox Pharmaceuticals trades on the NASDAQ under the ticker symbol "AQXP."
Where is Aquinox Pharmaceuticals' stock going? Where will Aquinox Pharmaceuticals' stock price be in 2017?
5 equities research analysts have issued 1-year price objectives for Aquinox Pharmaceuticals' stock. Their predictions range from $9.00 to $28.00. On average, they anticipate Aquinox Pharmaceuticals' stock price to reach $21.60 in the next year.
When will Aquinox Pharmaceuticals announce their earnings?
Aquinox Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
Who owns Aquinox Pharmaceuticals stock?
Aquinox Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (5.94%), Boxer Capital LLC (3.75%), Alyeska Investment Group L.P. (1.17%), Eventide Asset Management LLC (0.75%), Royce & Associates LP (0.68%) and State Street Corp (0.05%). Company insiders that own Aquinox Pharmaceuticals stock include Bros Advisors Lp Baker, David Chilton Mitchell, Kamran Alam and Lloyd Mackenzie.
Who sold Aquinox Pharmaceuticals stock? Who is selling Aquinox Pharmaceuticals stock?
Aquinox Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc. and Royce & Associates LP.
Who bought Aquinox Pharmaceuticals stock? Who is buying Aquinox Pharmaceuticals stock?
Aquinox Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC and Alyeska Investment Group L.P.. Company insiders that have bought Aquinox Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker and David Chilton Mitchell.
How do I buy Aquinox Pharmaceuticals stock?
Shares of Aquinox Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Aquinox Pharmaceuticals stock cost?
One share of Aquinox Pharmaceuticals stock can currently be purchased for approximately $18.29.